Voriconazole therapeutic drug monitoring. [Antimicrob Agents Chemother. 2006]

SearchDatabase nameforSearch term

Advanced Search (beta)

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2. Links

Voriconazole therapeutic drug monitoring.

Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D.

University of Wisconsin, Department of Medicine, Madison, WI 53792, USA.

We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P<0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 microg/ml, while disease progressed in 44% (n=18) of patients with concentrations below 2.05 microg/ml.

PMID: 16569888 [PubMed - indexed for MEDLINE]

PMCID: PMC1426935

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. [Clin Infect Dis. 2008]
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. [Swiss Med Wkly. 2006]
Random plasma concentrations of voriconazole decline over time. [J Infect. 2007]
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. [Cancer. 2007]
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. [Bone Marrow Transplant. 2005]
» See all Related Articles...

Patient Drug Information

Voriconazole (Vfend®) Voriconazole is used to treat serious fungal infections such as invasive aspergillosis (a fungal infection that begins in the lungs and spreads through the bloodstream to other organs) and esophageal candidiasis (infecti...

» read more ...

Display Show

Voriconazole therapeutic drug monitoring.

Related Articles